5 completed, 3 unknown, 1 withdrawn. 4 Phase 1, 3 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 3, Unknown 1 |
| Phase 3 | 3 | Completed 1, Unknown 1, Withdrawn 1 |
| Phase 2 | 1 | Unknown 1 |
Follow ISU Abxis Co., Ltd.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluate the Safety and Efficacy of Fabagal® (Agalsidase Beta) in Patients With Fabry Disease Fabagal® (Agalsidase beta), Active comparator (Agalsidase beta) - Fabry Disease | Phase 3 | Unknown | ISU Abxis Co., Ltd. | 24 | 2023-04-14 | 2024-07-29 |
| A Phase I Study to Compare Abcertin and EU-sourced Cerezyme® in Healthy Volunteers Abcertin, EU-sourced Cerezyme - Gaucher Disease | Phase 1 | Completed | ISU Abxis Co., Ltd. | 42 | 2020-01-29 | 2021-04-05 |
| Study of ISU104, Targeting ERBB3 in Patients With Advanced Solid Tumors ISU104, Cetuximab - Solid Tumor | Phase 1 | Unknown | ISU Abxis Co., Ltd. | 33 | 2018-04-27 | 2021-05-06 |
| Dose-escalation Study to Investigate the Safety, PK, and PD of ISU304/CB2679d in Hemophilia B Patients ISU304/CB2679d/Dalcinonacog alfa 75~150 IU/kg, BeneFIX - Hemophilia B | Phase 1 | Completed | ISU Abxis Co., Ltd. | 11 | 2017-06-03 | 2020-11-10 |
| Exploratory P2 Trial to Evaluate Efficacy and Safety of Clotinab® (Abciximab) in Acute MI Patients Abciximab, Placebo - Acute Myocardial Infarction | Phase 2 | Unknown | ISU Abxis Co., Ltd. | 146 | 2013-05-01 | 2017-03-22 |
| Phase III Study of ISU302 in Patients With Type 1 Gaucher Disease ISU302 - Gaucher Disease, Type 1 | Phase 3 | Completed | ISU Abxis Co., Ltd. | 8 | 2011-09-01 | 2017-07-12 |
| A Switch-Over Study of the Safety and Efficacy of ISU302 in Patients With Type 1 Gaucher Disease Gaucher Disease | Completed | ISU Abxis Co., Ltd. | 5 | 2011-05-01 | 2014-02-04 | |
| The Safety and Efficacy Study of ISU302 in Patient With Type I Gaucher Disease Cerezyme®, ISU302 - Gaucher Disease | Phase 3 | Withdrawn | ISU Abxis Co., Ltd. | 2011-01-01 | 2016-08-23 | |
| A Study of the Tolerability, Safety, and Pharmacokinetics of ISU302 in Healthy Volunteers ISU302, Placebo - Gaucher Disease | Phase 1 | Completed | ISU Abxis Co., Ltd. | 24 | 2010-10-01 | 2013-06-19 |
Gaucher Disease (5) · Breast Neoplasms (1) · Fabry Disease (1) · Head and Neck Neoplasms (1) · Hemophilia B (1)
imiglucerase (3) · Abcertin (1) · Abciximab (1) · Cetuximab (1) · ErbB Receptors (1) · Factor IX (1) · agalsidase beta (1)
South Korea (4) · Australia (1) · Philippines (1)
Amel El Beshlawy, Prof. (1) · Charlotte Lemech, MD (1) · ChurWoo You, PhD (1) · Jaehyeon Juhn, Ph.D (1) · Myungho Jeong (1)